BACKGROUND AIMS Baseline platelet count has been shown to be a sensitive predictor of autologous peripheral blood progenitor cell collection yield in patients with multiple myeloma mobilized with granulocyte colony-stimulating factor (G-CSF). Patients who mobilize poorly with G-CSF are often treated with plerixafor to enhance mobilization. There are no surrogate markers available to predict response to plerixafor. METHODS We retrospectively analyzed data from 73 patients with multiple myeloma who did not have adequate mobilization with G-CSF alone and were treated with plerixafor as a rescue agent. RESULTS We found that baseline platelet count directly correlated with peripheral blood CD34+ (PB-CD34+) count after plerixafor treatment (r = 0.36, P < 0.0001) and the number of PB-CD34+ cells collected on the first day of apheresis and inversely correlated with the number of apheresis sessions needed to collect the target number of PB-CD34+ cells (P = 0.0015). Baseline platelet count of 153 000/µL or less was associated with 90% specificity of predicting poor response to plerixafor with a sensitivity of 33%. CONCLUSIONS Baseline platelet count is a good predictor of mobilization response to plerixafor in patients with multiple myeloma.

中文翻译：

---

低基线血小板计数预示接受自体干细胞动员的多发性骨髓瘤患者对普乐沙福的反应不佳

背景 AIMS 基线血小板计数已被证明是使用粒细胞集落刺激因子 (G-CSF) 动员的多发性骨髓瘤患者自体外周血祖细胞收集率的敏感预测指标。G-CSF 活动能力差的患者通常使用普乐沙福治疗以增强活动能力。没有替代标记可用于预测对普乐沙福的反应。方法 我们回顾性分析了 73 名多发性骨髓瘤患者的数据，这些患者单独使用 G-CSF 不能充分动员并使用普乐沙福作为救援剂进行治疗。结果 我们发现，普乐沙福治疗后基线血小板计数与外周血 CD34+ (PB-CD34+) 计数直接相关（r = 0.36，P < 0. 0001) 和在单采第一天收集的 PB-CD34+ 细胞数量，并与收集目标数量的 PB-CD34+ 细胞所需的单采会议数量成反比 (P = 0.0015)。基线血小板计数为 153 000/µL 或更低与预测对普乐沙福不良反应的特异性为 90%，敏感性为 33%。结论 基线血小板计数是多发性骨髓瘤患者对普乐沙福动员反应的良好预测指标。